PATENT CLAIM ANALYSIS

Application Number: 16028140
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-06
Patent Classification: ["424", "133100"]

Abstract:
The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn wider an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Claim (Index 70):
The method of  claim 69 , wherein at least one position from the following positions (all by EU numbering) is substituted with the indicated amino acid:\n position 244: Leu; position 245: Arg; position 249: Pro; position 250: Gln or Glu; position 251: Arg, Asp, Glu, or Leu; position 252: Phe, Ser, Thr, or Tyr; position 254: Ser or Thr; position 255: Arg, Gly, Ile, or Leu; position 256: Ala, Arg, Asn, Asp, Gln, Glu, Pro, or Thr; position 257: Ala, Ile, Met, Asn, Ser, or Val; position 258: Asp; position 260: Ser; position 262: Leu; position 270: Lys; position 272: Leu or Arg; position 279: Ala, Asp, Gly, His, Met, Asn, Gln, Arg, Ser, Thr, Trp, or Tyr; position 283: Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Asn, Pro, Gln, Arg, Ser, Thr, Trp, or Tyr; position 285: Asn; position 286: Phe; position 288: Asn or Pro; position 293: Val; position 307: Ala, Glu, Gln, or Met; position 308: Ile, Pro, or Thr; position 309: Pro, position 311: Ala, Glu, Ile, Lys, Leu, Met, Ser, Val, or Trp; position 312: Ala, Asp, or Pro; position 314: Ala or Leu; position 316: Lys; position 317: Pro; position 318: Asn or Thr; position 332: Phe, His, Lys, Leu, Met, Arg, Ser, or Trp; position 339: Asn, Thr, or Trp; position 341: Pro; position 343: Glu, His, Lys, Gln, Arg, Thr, or Tyr; position 375: Arg; position 376: Gly, Ile, Met, Pro, Thr, or Val; position 377: Lys; position 378: Asp, Asn, or Val; position 380: Ala, Asn, Ser, or Thr; position 382: Phe, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, or Tyr; position 385: Ala, Arg, Asp, Gly, His, Lys, Ser, or Thr; position 386: Arg, Asp, Ile, Lys, Met, Pro, Ser, or Thr; position 387: Ala, Arg, His, Pro, Ser, or Thr; position 389: Asn, Pro, or Ser; position 423: Asn; position 427: Asn; position 428: Leu, Met, Phe, Ser, or Thr; position 430: Ala, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, or Tyr; position 431: His or Asn; position 433: Arg, Gln, His, Ile, Lys, Pro, or Ser; position 434: Ala, Gly, His, Phe, Ser, Trp, or Tyr; position 436: Arg, Asn, His, Ile, Leu, Lys, Met, or Thr; position 438: Lys, Leu, Thr, or Trp; position 440: Lys; position 442: Lys.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 95.0
- Lexical Diversity: 1.5974
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14007947', '14347448', '14101441', '13650493', '09825517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7654589544858276
- 35 USC 102 Novelty (BERT): 0.7753820611088865
- Combined Prediction Score: 0.7664512651481336
- Mean Citation Score: 761.1392320000001
- Max Citation Score: 1081.3811
- Similarity Product: 912.2334101658704

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test